This is a summary of the European public assessment report (EPAR) for Aripiprazole Accord. It explains how the Agency assessed the medicine to recommend its authorisation in the EU and its conditions of use. It is not intended to provide practical advice on how to use Aripiprazole Accord. For practical information about using Aripiprazole Accord, patients should read the package leaflet or contact their doctor or pharmacist.
Therapeutic Indication
### Therapeutic indication Aripiprazole Accord is indicated for the treatment of schizophrenia in adults and in adolescents aged 15 years and older. Aripiprazole Accord is indicated for the treatment of moderate to severe manic episodes in Bipolar I Disorder and for the prevention of a new manic episode in adults who experienced predominantly manic episodes and whose manic episodes responded to aripiprazole treatment. Aripiprazole Accord is indicated for the treatment up to 12 weeks of moderate to severe manic episodes in Bipolar I Disorder in adolescents aged 13 years and older.
Therapeutic Area (MeSH)
N/AATC Code
N05AX12
ATC Item
aripiprazole
Pharmacotherapeutic Group
Psycholeptics
Active Substance (Summary)
INN / Common Names
N/A| Substance | CAS | Monograph |
|---|---|---|
| aripiprazole | N/A | 阿立哌唑 |
EMA Name
Aripiprazole Accord
Medicine Name
Aripiprazole Accord
Aliases
N/ANo risk management plan link.
